AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Exosome complex component RRP46

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NQT4

UPID:

EXOS5_HUMAN

Alternative names:

Chronic myelogenous leukemia tumor antigen 28; Exosome component 5; Ribosomal RNA-processing protein 46; p12B

Alternative UPACC:

Q9NQT4; Q32Q81; Q8NG16; Q96I89

Background:

Exosome complex component RRP46, also known as Exosome component 5 or Chronic myelogenous leukemia tumor antigen 28, plays a crucial role in RNA processing and degradation. It is a non-catalytic component of the RNA exosome complex, involved in the maturation of stable RNA species, elimination of RNA processing by-products, and degradation of unstable mRNAs. This protein's activity is essential in both the nucleus and the cytoplasm for maintaining RNA homeostasis.

Therapeutic significance:

The involvement of Exosome complex component RRP46 in cerebellar ataxia, brain abnormalities, and cardiac conduction defects highlights its potential as a therapeutic target. Understanding the role of Exosome complex component RRP46 could open doors to potential therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.